Previous 10 |
NEW HAVEN, Conn., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today its preliminary unaudited 2018 Revenues of $2.8M, representing 66% growth over 2017 Revenues of $1.7M. Furthermore, fourth quarter financials demonstrat...
NEW HAVEN, Conn., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced a recent radio show interview of Ilan Danieli, Precipio’s CEO, on the New York Nassau Community College Radio station. The interview addressed the...
Precipio ICE COLD-PCR™ reagents will be sold with PerkinElmer DNA/RNA extraction and isolation products NEW HAVEN, Conn., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) today announced an agreement with PerkinElmer to ...
Enables Company to execute on strategic and commercial initiatives with the goal of meeting the minimum $1.00 price target NEW HAVEN, Conn., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ:PRPO ), today announced notification by the N...
New kit examines most relevant EGFR exons that impact therapeutic decisions for lung cancer patients NEW HAVEN, Conn., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. ( NASDAQ: PRPO ), announced today the launch of a new ICEme™ kit using its proprietary, ultra-sensi...
Redwood City, CA-based Guardant Health ( GH ) has filed a prospectus for a $100M IPO. More news on: Guardant Health, TrovaGene, Inc., Roche Holding Ltd ADR, Healthcare stocks news, IPOs, Read more ...
Precipio, Inc. (PRPO) Q2 2018 Results Earnings Conference Call August 23, 2018, 09:00 AM ET Executives Company Representative - Ilan Danieli - CEO Carl Iberger - CFO Analysts Presentation Operator Good morning, and welcome to Precipio's Quarterly Shareholder Update...
Provides participation details for Thursday, August 23 call NEW HAVEN, Conn., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), wishes to remind investors and shareholders of its previously announced shareholder conference call scheduled...
News, Short Squeeze, Breakout and More Instantly...
NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Patholog...
NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted...
NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to e...